Egf1.0 inhibits PAP1 amidolytic activity. Recombinant Egf1.0,
Egf1.0ΔRD, Egf1.0ΔCD, Egf1.0R51A, or Egf0.4 (4 pmol)
was added to purified PAP-1 (0.4 pmol) plus substrate for 10 min. PAP1 plus
substrate alone served as the control (Cont). The asterisk
indicates treatment with significantly lower amidase activity compared with
the control (F5, 17 = 20.2; p < 0.001; followed by
Dunnett's multiple comparison procedure).